Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02221882 | A Study of LY3164530 in Participants With Cancer | PHASE1 | COMPLETED | 29 | — | — | Aug 1, 2014 | Mar 7, 2017 | Oct 23, 2019 | 3 | United States |
Recommended Phase 2 Dose of LY3164530: MTD
| Arm | Type | Description |
|---|---|---|
| LY3164530 | EXPERIMENTAL | LY3164530 in escalating dose cohorts given intravenously (IV) once on Days 1 and 15 or on Days 1, 8, 15, and 22 of a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met. |
| Name | Type | Description |
|---|---|---|
| LY3164530 | DRUG | Administered IV. |
Inclusion Criteria * Have advanced or metastatic cancer and be an appropriate candidate for experimental therapy. * Have adequate organ function. * Prior Treatments: * Systemic treatments: Must have discontinued previous systemic treatments for cancer and recovered from the acute effects of ther...